
    
      Study 990 is a Phase IIa, proof-of-concept study of BT063 in subjects with SLE. This study is
      divided into 2 parts. After Part I an interim analysis will be performed. Each Part will
      enrol 18 subjects. Subjects will be randomly assigned to receive BT063 or Placebo 8 times
      over 12 weeks and will be followed for 4 months after their last dose.
    
  